Details
Stereochemistry | ACHIRAL |
Molecular Formula | C24H28N6O3S |
Molecular Weight | 480.583 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)CCNS(=O)(=O)CC1=CC=CC(NC2=NC=CC(OC3=CC=C4NC(C)=CC4=C3)=N2)=C1
InChI
InChIKey=TTZSNFLLYPYKIL-UHFFFAOYSA-N
InChI=1S/C24H28N6O3S/c1-17-13-19-15-21(7-8-22(19)27-17)33-23-9-10-25-24(29-23)28-20-6-4-5-18(14-20)16-34(31,32)26-11-12-30(2)3/h4-10,13-15,26-27H,11-12,16H2,1-3H3,(H,25,28,29)
Sulfatinib (previously known as HMPL-012) was developed as a small-molecule inhibitor targeting vascular endothelial growth factor receptors 1 and 3, fibroblast growth factor receptor 1 and colony-stimulating factor 1 receptor with potential antineoplastic and anti-angiogenic activities. Sulfatinib has shown encouraging antitumor activity and manageable toxicities in patients with advanced neuroendocrine tumors (NET). The drug is participating in two ongoing phases III studies, validating the efficacy of surufatinib in patients with NETs. In addition, in November 2018, Hutchison MediPharma completed a phase II trial of sulfatinib, for the treatment of patients with biliary tract cancer. This drug is also participating in the phase II trial that is currently in recruiting status in treating advanced medullary thyroid carcinoma.
Originator
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT02588170
SULFATINIB (HMPL-012) 300 mg once a day (QD) will be orally administrated on a 28-day cycle
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
710319
Created by
admin on Sat Dec 16 08:44:53 GMT 2023 , Edited by admin on Sat Dec 16 08:44:53 GMT 2023
|
||
|
NCI_THESAURUS |
C93259
Created by
admin on Sat Dec 16 08:44:53 GMT 2023 , Edited by admin on Sat Dec 16 08:44:53 GMT 2023
|
||
|
NCI_THESAURUS |
C129825
Created by
admin on Sat Dec 16 08:44:53 GMT 2023 , Edited by admin on Sat Dec 16 08:44:53 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
52920501
Created by
admin on Sat Dec 16 08:44:53 GMT 2023 , Edited by admin on Sat Dec 16 08:44:53 GMT 2023
|
PRIMARY | |||
|
1816307-67-1
Created by
admin on Sat Dec 16 08:44:53 GMT 2023 , Edited by admin on Sat Dec 16 08:44:53 GMT 2023
|
SUPERSEDED | |||
|
HI-176
Created by
admin on Sat Dec 16 08:44:53 GMT 2023 , Edited by admin on Sat Dec 16 08:44:53 GMT 2023
|
PRIMARY | |||
|
C116066
Created by
admin on Sat Dec 16 08:44:53 GMT 2023 , Edited by admin on Sat Dec 16 08:44:53 GMT 2023
|
PRIMARY | |||
|
1308672-74-3
Created by
admin on Sat Dec 16 08:44:53 GMT 2023 , Edited by admin on Sat Dec 16 08:44:53 GMT 2023
|
PRIMARY | |||
|
DB15106
Created by
admin on Sat Dec 16 08:44:53 GMT 2023 , Edited by admin on Sat Dec 16 08:44:53 GMT 2023
|
PRIMARY | |||
|
100000181191
Created by
admin on Sat Dec 16 08:44:53 GMT 2023 , Edited by admin on Sat Dec 16 08:44:53 GMT 2023
|
PRIMARY | |||
|
B2K5L1L8S9
Created by
admin on Sat Dec 16 08:44:53 GMT 2023 , Edited by admin on Sat Dec 16 08:44:53 GMT 2023
|
PRIMARY | |||
|
10349
Created by
admin on Sat Dec 16 08:44:53 GMT 2023 , Edited by admin on Sat Dec 16 08:44:53 GMT 2023
|
PRIMARY | |||
|
CHEMBL3545251
Created by
admin on Sat Dec 16 08:44:53 GMT 2023 , Edited by admin on Sat Dec 16 08:44:53 GMT 2023
|
PRIMARY |
ACTIVE MOIETY